Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1062 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Not yet recruiting Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer
Condition: Bronchial Cancer
Intervention: Device: With and without SDB
4 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
5 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
6 Not yet recruiting Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Durvalumab;   Other: Durvalumab plus SBRT
7 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
8 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
9 Not yet recruiting Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
Conditions: EGFR Gene Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nimotuzumab;   Biological: Nivolumab
10 Not yet recruiting Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Radiation: hypofractionated radiotherapy;   Drug: Pemetrexed;   Drug: Etoposide
11 Not yet recruiting ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
Conditions: Non-small Cell Lung Cancer Stage III;   Non-Small-Cell Lung Cancer Metastatic;   Adenocarcinoma of Lung;   EGFR Wildtype
Intervention: Genetic: ctDNA analysis
12 Recruiting Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Condition: Small Cell Lung Cancer
Intervention: Drug: apatinib
13 Not yet recruiting Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: veliparib;   Drug: nivolumab;   Drug: carboplatin;   Drug: pemetrexed;   Drug: paclitaxel
14 Recruiting Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Condition: Malignant Pleural Effusion
Intervention: Drug: Bevacizumab
15 Not yet recruiting A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions: Locally Advanced Squamous Non-Small Cell Lung Cancer;   Metastatic Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Necitumumab;   Drug: Gemcitabine;   Drug: Carboplatin
16 Not yet recruiting Anti PD-1 Neo-adjuvant Treatment for NSCLC
Conditions: Non Small Cell Lung Carcinoma;   Stage I;   Stage II
Interventions: Drug: Pembrolizumab 200 mg IV single dose;   Drug: Pembrolizumab 200 mg IV twice interval 21 days;   Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d;   Drug: Pembrolizumab 100 mg I.V single dose;   Procedure: Surgical resection of tumor
17 Not yet recruiting 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
Condition: Non-small-cell Lung Cancer
Intervention: Radiation: 18F-FDG
18 Not yet recruiting A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Condition: Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Interventions: Drug: Durvalumab and Tremelimumab;   Drug: AZD1775 and carboplatin (CBPT)
19 Not yet recruiting Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Carcinoma;   Small Cell Lung Carcinoma
Interventions: Procedure: Bronchoscopy with Bronchoalveolar Lavage;   Other: Laboratory Biomarker Analysis
20 Not yet recruiting PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Conditions: Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
Intervention: Drug: PEN-221

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years